Betimol
NDC 76478-002
Product Information
Betimol is a NDA-approved product labeled by Akorn. This medication is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (e. It is supplied as a product. This product entry covers the primary NDC 76478-002 and 4 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 76478-002?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- TIMOLOL (UNII: 817W3C6175)
- TIMOLOL ANHYDROUS (UNII: 5JKY92S7BR) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE (UNII: 5QWK665956)
- SODIUM PHOSPHATE, DIBASIC, DIHYDRATE (UNII: 94255I6E2T)
- WATER (UNII: 059QF0KO0R)
- BENZALKONIUM CHLORIDE (UNII: F5UM2KM3W7)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1992305 - BETIMOL 0.5 % Ophthalmic Solution
- RxCUI: 1992305 - timolol hemihydrate 5 MG/ML Ophthalmic Solution [Betimol]
- RxCUI: 1992305 - Betimol 0.5 % Ophthalmic Solution
- RxCUI: 1992305 - Betimol 5 MG/ML (as timolol hemihydrate 5.12 MG/ML) Ophthalmic Solution
- RxCUI: 208560 - BETIMOL 0.25 % Ophthalmic Solution
* Please review the full disclaimer at the bottom of this page.
Patient Education
Timolol Ophthalmic
Ophthalmic timolol is used to treat glaucoma, a condition in which increased pressure in the eye can lead to gradual loss of vision. Timolol is in a class of medications called beta-blockers. It works by decreasing the pressure in the eye.
[Learn More]
* Please review the full disclaimer at the bottom of this page.